Wellington Partners

Wellington Partners

  • Home
  • Team
  • Approach
  • Portfolio
  • News
  • Contact

News

CEPI awards up to US$21 million to Themis for Phase 3 Chikungunya Vaccine Development

Details
Published: 04 June 2019
  • portfolio-news

Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a second partnering agreement under which CEPI, with support from the EU’s Horizon 2020 programme, will provide up to US$21 million of non-dilutive capital for Themis’ Phase 3-ready Chikungunya vaccine (MV-CHIK). The funding will underwrite a collaborative effort to accelerate regulatory approval of Themis’ Chikungunya vaccine and ensure that at-risk populations have access to the vaccine. 

© Wellington Partners, 2021.
  • WP Technology Funds
  • Contact
  • Imprint
  • Privacy